Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
36.54
-0.96 (-2.56%)
At close: Oct 7, 2025, 4:00 PM EDT
36.35
-0.19 (-0.52%)
After-hours: Oct 7, 2025, 7:44 PM EDT
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $27.77M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $572.98M, up 2,816.21% year-over-year. In the fiscal year ending September 30, 2024, Arrowhead Pharmaceuticals had annual revenue of $3.55M, down -98.52%.
Revenue (ttm)
$572.98M
Revenue Growth
+2,816.21%
P/S Ratio
8.31
Revenue / Employee
$940,847
Employees
609
Market Cap
5.05B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ARWR News
- 18 hours ago - Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - Business Wire
- 8 days ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 26 days ago - Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals - Business Wire
- 27 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 27 days ago - Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript - Seeking Alpha
- 4 weeks ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript) - Seeking Alpha